Bimekizumab - UCB
Alternative Names: Anti-IL-17-mAb-UCB; Anti-IL-17-monoclonal-antibody-UCB; Anti-interleukin-17-monoclonal-antibody-UCB; bimekizumab-bkzx; BIMZELX; Bimzelx; BKZ; CDP-4940; UCB-4940Latest Information Update: 24 Jul 2024
At a glance
- Originator UCB
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erythrodermic psoriasis; Plaque psoriasis; Pustular psoriasis
- Registered Axial spondyloarthritis; Hidradenitis suppurativa; Psoriatic arthritis
- Preregistration Ankylosing spondylitis
- No development reported Psoriasis
- Discontinued Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 12 Jul 2024 UCB Biopharma plans a phase IIIb for Plaque Psoriasis(SC)(NCT06506916) (EUCT2023-506333-29-00 ) in July 2024
- 12 Jun 2024 Efficacy data from phase III BE MOVING clinical trial in Ankylosing spondylitis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 07 Jun 2024 Phase-III clinical trials in Plaque psoriasis (In adolescents, In children) in USA (SC) (NCT06425549) (EudraCT-2023-503859-10-00)